[1]郭 悦,刘纯兴,于艳丽.心梗救逆汤治疗急性冠脉综合征疗效及对患者心室重构风险的影响[J].陕西中医,2022,(9):1215-1218.[doi:DOI:10.3969/j.issn.1000-7369.2022.09.014]
　GUO Yue,LIU Chunxing,YU Yanli.Effects of Xingeng Jiuni decoction on patients with actue coronary syndrome and the risk of ventricular remodeling[J].,2022,(9):1215-1218.[doi:DOI:10.3969/j.issn.1000-7369.2022.09.014]
点击复制

心梗救逆汤治疗急性冠脉综合征疗效及对患者心室重构风险的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年9期
页码:
1215-1218
栏目:
临床研究
出版日期:
2022-09-05

文章信息/Info

Title:
Effects of Xingeng Jiuni decoction on patients with actue coronary syndrome and the risk of ventricular remodeling
作者:
郭 悦1; 刘纯兴2; 于艳丽1
(1.辽宁中医药大学附属医院,辽宁 沈阳 110032; 2.沈阳医学院附属第二医院,辽宁 沈阳 110002)
Author(s):
GUO Yue; LIU Chunxing; YU Yanli
(Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China)
关键词:
急性冠脉综合征;  心梗救逆汤;  转化生长因子-β;  结缔组织生长因子;  心室重构;  心肌纤维化;  心功能
Keywords:
Acute coronary syndrome;  Xingeng Jiuni decoction;  Transforming growth factor-β;  Connective tissue growth factor;  Ventricular remodeling;  Myocardial fibrosis;  Heart function
分类号:
R 543.3
DOI:
DOI:10.3969/j.issn.1000-7369.2022.09.014
文献标志码:
A
摘要:
目的:探讨心梗救逆汤对急性冠脉综合征患者转化生长因子-β(TGF-β)和结缔组织生长因子(CCN2)水平及心室重构风险的影响。方法:选取80例急性冠脉综合征患者为研究对象,根据随机数字表法分为研究组和对照组,每组40例。对照组予以常规治疗,研究组在对照组的基础上予以心梗救逆汤治疗。治疗4周后,比较两组患者临床疗效、中医证候积分、心功能、CCN2、TGF-β及不良反应情况。随访6个月,记录两组患者心室重构情况,分析心梗救逆汤对急性冠脉综合征患者心室重构风险的影响。结果:治疗后,研究组临床总有效率高于对照组(P<0.05)。治疗后,研究组中医证候积分低于对照组(P<0.05)。治疗后,研究组左室舒张末直径(LVEDD)、左室质量指数(LVM)低于对照组(均P<0.05)。治疗后,研究组左室搏出量(LVSV)、左室射血分数(LVEF)高于对照组(均P<0.05)。治疗后,研究组CCN2、TGF-β水平低于对照组(均P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。Kaplan-Meier曲线分析显示,研究组心室重构风险低于对照组(P<0.05)。结论:心梗救逆汤治疗急性冠脉综合征可提高临床疗效,改善中医证候积分,降低结缔组织生长因子水平,改善心功能,缓解心室重构进程,且未明显增加患者不良反应。
Abstract:
Objective:To investigate effect of Xingeng Jiuni decoction on the levels of transforming growth factor-β(TGF-β),connective tissue growth factor(CCN2)and the risk of ventricular remodeling in patients with acute coronary syndrome.Methods:80 patients with acute coronary syndrome as the research objects.According to the random number table method,they were divided into study group and control group,with 40 cases in each group.The control group received conventional treatment,and the study group treated with Xingeng Jiuni decoction on the basis of the control group.After 4 weeks of treatment,clinical efficacy,TCM syndrome score,cardiac function,CCN2,TGF-β and adverse reactions between the two groups were compared.Follow up for 6 months,recorded the ventricular remodeling of the two groups,analyze the influence of Xingeng Jiuni decoction on the risk of ventricular remodeling in patients with acute coronary syndrome.Results:After treatment,the total clinical effective rate of the study group was higher than that of the control group(P<0.05).The TCM symptom scores in the study group were lower than those in the control group(P<0.05).After treatment,the levels of LVEDD and LVM in the study group were lower than those in the control group(all P<0.05).After treatment,the levels of LVSV and LVEF in the study group were higher than those in the control group(all P<0.05).The levels of CCN2 and TGF-β in the study group were lower than those in the control group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Kaplan-Meier curve analysis showed that the risk of ventricular remodeling in the study group was lower than that in the control group(P<0.05).Conclusion:Xingeng Jiuni decoction in the treatment of patients with acute coronary syndrome can effectively improve clinical efficacy,TCM symptom score,effectively reduce connective tissue growth factor,improve cardiac function,relieve the process of ventricular remodeling,and does not increase the incidence of reaction.

参考文献/References:

[1] 刘江萍,木胡牙提.急性冠脉综合征流行病学及危险因素的研究进展[J].国际心血管病杂志,2019,46(1):1-3,7.
[2] 刘美林,袁 博,赵 伟,等.急性冠状动脉综合征患者循环miR-208b-3p与心室重构的关系研究[J].中国心血管病研究,2019,17(2):156-160.
[3] 殷云杰,陈燕春,杨 松.心肌纤维化机制研究进展[J].中华老年多器官疾病杂志,2019,18(7):540-543.
[4] 李 悦,石 静,何美娇.急性冠状动脉综合征患者抗栓降阶治疗研究进展[J].临床心血管病杂志,2020,36(12):1075-1078.
[5] 朱火兰,杜 洁,潘 硕,等.急性冠脉综合征患者GRACE评分与氯吡格雷抵抗相关性分析[J].陕西医学杂志,2017,46(10):1412-1414.
[6] 李同一,李泉红.急性冠脉综合征与血清炎症因子的中西医研究进展[J].中国中医急症,2020,29(10):1869-1872,1880.
[7] 刘建兴,王秀从.心梗救逆汤联合西药治疗急性心肌梗死的临床效果观察[J].中西医结合心血管病电子杂志,2018,6(24):169.
[8] Lo SH,Hsu CT,Niu HS,et al.Ginsenoside Rh2 improves cardiac fibrosis via PPARδ-STAT3 signaling in type 1-like diabetic rats[J].Int Journal Mol Sci,2017,18(7):1364.
[9] 王北婴.中药治疗胸痹临床研究指导原则[J].中国医药学报,1987,2(6):46-52.
[10] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会.急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404.
[11] Dong C,Ma A,Shang L.Nanoparticles for postinfarct ventricular remodeling[J].Nanomedicine,2018,13(23):3037-3050.
[12] 户丽娟.金匮肾气丸合桃红四物汤联合西药治疗慢性心力衰竭疗效及对患者心率变异性、左室重构和肾功能的影响[J].陕西中医,2021,42(11):1576-1580.
[13] 方子寒,谢盈彧,张军平.急性冠状动脉综合征中医诊治概述[J].中华中医药学刊,2019,37(8):1852-1855.
[14] 韩 笑,单 伟.黄连素通过调控炎症水平抑制老年大鼠心肌梗死后心室重构实验研究[J].陕西医学杂志,2020,49(1):7-11.
[15] 刘耀武.四逆汤联合溶栓治疗急性心肌梗死缺血再灌注损伤及对患者动态心电图和SOD、CK-MB、LDH的影响[J].陕西中医,2019,40(7):858-860.
[16] 吴 滨.益气活血化痰法对气虚痰瘀型急性冠脉综合征患者疗效及脂代谢的影响[J].陕西中医,2017,38(2):167-168.
[17] 刘学安,喻晶晶.大株红景天注射液对急性冠脉综合征患者血运重建后心肌缺血-再灌注损伤的作用[J].陕西中医,2017,38(7):871-873.
[18] Ma S,Ma J,Guo L,et al.Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts[J].Journal Cell Mol Med,2019,23(2):1197-1210.
[19] Kim JH,Choi JS.Effect of ginsenoside Rh-2 via activation of Caspase-3 and Bcl-2 insensitive pathway in ovarian cancer cells[J].Physiol Res,2016,65(6):1031-1037.
[20] Zhou YS,Mao S,Guo LH,et al.Effect of Tongguan capsules on restenosis after coronary stent implantation:Study protocol for a randomized controlled trial[J].Chin Journal Integr Med,2021,27(1):16-23.

更新日期/Last Update: 2022-09-08